Aurinia Q4 2024 net income $1.4M on 33% revenue growth, LUPKYNIS sales up 36% YoY

Aurinia Pharmaceuticals Inc.

2024-FY EPS reported $0.04 revenue$235,133,000

Q4 total revenue $59.9M (+33% YoY); net product sales $57.6M (+36%); license revenue $2.3M (-18%).
Q4 net income $1.4M vs $(26.9)M loss; full year net income $5.8M vs $(78.0)M loss.
Cash flow from operations Q4 $30.1M (+110% YoY); full year $44.4M vs $(33.5)M.
2025 guidance: total revenue $250-260M, net product sales $240-250M; AUR200 Phase 1 data expected Q2 2025.
Cash $358.5M at Dec 31, 2024; repurchased 6.1M shares for $41M in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.